Last update Dec. 30, 2022
Compatible
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Maternal osteoporosis belongs to this group or family:
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Breatfeeding is associated with transient bone loss, with full recovery of bone mineral density (BMD) within 6 - 12 months after weaning, which minimizes any significant damage to the maternal skeleton. (Capozzi 2021, Oboh 2021, Grizzo 2020, Sowers 1993)
The relationship between breastfeeding and its duration with osteoporosis and the risk of postmenopausal fracture (hip or others) is highly controversial, since while:
The diagnosis of osteoporosis during pregnancy or breastfeeding does not contraindicate breastfeeding. An adequate intake of calcium and vitamin D is important during pregnancy and lactation, through a balanced diet and regular exercise and with the help of dietary supplements if necessary.
Most osteoporosis treatments are compatible with breastfeeding.
Only in the rare disease known as Pregnancy and Lactation-associated Osteoporosis (PLO) is suppression of breastfeeding indicated. (Lujano 2022, Jun 2020, Jia 2020, Cohen 2019)
See below the information of these related products:
See below the information of this related group: